AMPIO PHARMACEUTICALS, INC.: 10-Q filed 2015-11-06
What AMPIO PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-11-06 (fiscal Q3 2015): 25 published measures, 61 facts as tagged in accession 0001193125-15-370152.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-11-06
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001193125-15-370152 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All AMPIO PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 57,079,495 | USD | |
| At 2014-12-31 | 70,268,410 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 10,613,014 | USD | |
| At 2014-12-31 | 4,809,892 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 44,922,160 | USD | |
| At 2014-12-31 | 66,118,265 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 35,384,904 | USD | |
| At 2014-12-31 | 50,320,656 | USD | |
| At 2014-09-30 | 56,830,455 | USD | |
| At 2013-12-31 | 26,309,449 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -7,365,540 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -22,004,550 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -9,280,030 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -28,213,733 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 112,263 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 7,925,198 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 487,385 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 693,249 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 21,429 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 55,358 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -123,909,120 | USD | |
| At 2014-12-31 | -101,904,570 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 9,418,940 | USD | |
| At 2014-12-31 | 9,945,428 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 4,088,437 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 5,124,187 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -7,672,210 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -22,994,062 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -9,497,212 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -28,912,670 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 37,241,897 | USD | |
| At 2014-12-31 | 51,259,157 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 3,895,996 | USD | |
| At 2014-12-31 | 3,679,983 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 2,310,615 | USD | |
| At 2014-12-31 | 3,299,025 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 74,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 611,079 | USD | |
| At 2014-12-31 | 664,169 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 3,410,920 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 10,379,173 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,299,043 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 9,261,938 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 51,998,306 | shares | |
| At 2014-12-31 | 51,972,266 | shares |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 46,466,481 | USD | |
| At 2014-12-31 | 65,458,518 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 1,058,000 | USD | |
| At 2014-12-31 | 419,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 1,530,375 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -7,786,635 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -23,091,734 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -9,491,665 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -28,896,123 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -114,425 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -97,672 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 5,547 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 16,547 | USD | 273 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 68,409,531 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -988,410 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 174,662 | USD | 273 |
Inspect the source
- Entity
- AMPIO PHARMACEUTICALS, INC. / CIK 0001411906
- Captured
- SEC response SHA-256
661bdc81760eff21f73144c4212b3daf37fe49f00b5469e6e153f0c2138a63e3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001411906.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))